Digital information and support app for people starting neoadjuvant therapy for pancreatic cancer
Official title: PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Run by Massachusetts General Hospital · NCT07047807 · Data updated 2026-11-12
This pilot will test whether the PDAC-PATHWAYS app is feasible and acceptable for people starting neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | October 6, 2025 |
| Main results expected | May 2027 |
| Study ends | August 2027 |
| Registry record updated | July 29, 2026 |
| Trial ID | NCT07047807 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with newly diagnosed, non-metastatic PDAC who are within eight weeks of deciding to start neoadjuvant therapy and who can read and speak English.
✕Probably not a fit
Patients with significant comorbid conditions that interfere with participation, non-English speakers, or those already receiving similar digital support may not receive benefit from this specific intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PDAC-PATHWAYS is a digital app that provides informational and supportive-care content for patients initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma. The overall program has two parts: an open pilot to refine the app (Part 1) and a pilot randomized controlled component (Part 2) that randomizes participants to PDAC-PATHWAYS versus usual care after a baseline survey. This record describes Part 2, which will collect feasibility and acceptability outcomes to determine whether a larger randomized trial is practical. Eligible participants are adults within eight weeks of deciding to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC who can read and speak English, with exclusion for comorbid conditions that would interfere with participation.
Why it matters
Potential benefit: If successful, the app could improve patient education, symptom management, and emotional support during neoadjuvant therapy.
How similar studies have gone: Digital supportive-care apps have shown promise in other cancer populations for improving symptom management and patient experience, but PDAC-specific randomized data are limited, so this application is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥18 years * Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC * Able to comprehend and speak English Exclusion Criteria: * Comorbid health condition that would interfere with study participation, as identified by the cancer care team
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Kelsey Lau-Min, MD, MSCE
- Email: klau-min@mgh.harvard.edu
- Phone: 617-724-4000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted 4D PET imaging to detect early pancreatic cancer lesions
This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.
-
Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer
This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.
-
Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults
A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.
-
Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer
This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.
-
Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer
This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.
-
Personalised Functional Profiling in colorectal cancer and pancreatic cancer
This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.